Pharmacy Times August 27, 2025
Samar Nicolas, PharmD, RPh, CPPS, Abir O. Kanaan, PharmD, RPh

Key Takeaways

  • CT-152, a smartphone app, combines cognitive-emotional training and CBT to improve MDD symptoms by enhancing brain connectivity related to emotion processing.
  • A phase 3 trial showed CT-152’s safety and efficacy as an adjunct to antidepressant therapy, with significant improvement in depression symptoms.
  • The app provides a nonpharmacologic option, reducing the risk of medication-related adverse effects, and is eligible for HSA and FSA reimbursement.
  • Consultant pharmacists and nurse practitioners should consider CT-152 for patients with inadequate response to antidepressant therapy, especially when concerned about medication-related adverse effects.

Digital therapeutics (DTx) are digital health tools that the FDA and other regulatory agencies have reviewed and authorized to deliver validated medical interventions.1 In 2025, the Journal of Affective Disorders...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: Apps, Digital Health, Mental Health, Provider, Technology
Related Articles:
The Medical Futurist’s 100 Digital Health And AI Companies Of 2026
The $20B Opportunity: Transforming Unused Health Data into a Strategic Asset
Canada: Acute Care EHR & Digital Health 2026-What's Changing Now in Adoption, Implementation, Selection and Satisfaction - Black Book Research
Digital Health Solutions at CES 2026
Two App Updates Make The Apple Watch Even Better For Fitness Tracking

Share Article